Topic: ulcerative colitis


10. Stelara

Johnson & Johnson's stalwart immunology blockbuster Stelara has been a steady earner for years. But with some areas of its portfolio lagging behind, J&J is hoping that pushing Stelara into new markets can help overcome those stumbles—and keep Stelara generating significant sales for years to come. 
Pfizer sign

3. Pfizer

Pfizer totted up a list of accomplishments and milestones in 2018, besides the fact that it managed to eke out growth of about 2% for the year. It reorganized into three business units, for instance, reviving talk of an eventual generics spinoff and setting up its consumer health business for easier disposal.